The evoked response to repeated auditory stimuli generally decreases in amplitude, a phenomenon that demonstrates the activity of sensory gating mechanisms in the central nervous system (CNS). Gating of the PSO wave of the auditory evoked response shows such behavior in normals, but not in schizophrenic or manic subjects. In mania, diminished gating of the auditory evoked response is correlated with elevated levels of noradrenergic metabolites. In animals, yohimbine, a presynaptic a-2 antagonist, increases noradrenergic neuronal transmission in the CNS and diminished gating of the auditory evoked response. The aim of this
experiment was to test whether yohimbine causes diminished auditory sensory gating in normal human controls. Seven normal subjects with normal PSO auditory gating were treated either with 0.4 mglkg of oral yohimbine on one day or placebo on a different day. Each subject acted as his own control. Yohimbine, but not placebo, caused a significant but transient decrease in PSO auditonj gating in these subjects. Thus, increasing CNS noradrenergic neuronal transmission in normal controls can cause a transient impairment in auditory sensory gating. [Neuropsychopharmacology 10:249-257, 1994J jects decrease the amplitude of the P50 waveform in response to the second of two auditory clicks presented 500 msec apart (Chapman et al. 1981; Davis et al. 1966; Erwin and Buchwald 1986; Finkenzeller and Keidel 1975; Fruhstorfer et al. 1970; Papanicolau et al. 1984 Papanicolau et al. , 1985 Roth and Kopell 1969) . Many psychiatrically ill subjects, including most psychotic patients, do not (Adler et al. 1982 Freedman et al. 1983; Franks et al. 1983; Baker et al. 1987 Baker et al. , 1990 Boutros et al. 1991; Judd et al. 1992; Erwin et al. 1991; Siegel et al. 1984; Waldo and Freedman 1986) .
There is also increasing evidence that some defIcits of P50 auditory gating may reflect increased catechol arninergic activity. For example, manic patients have impaired P50 auditory gating when acutely psychotic, but when they are euthyrnic, their P50 gating is indis tinguishable from that of normal controls Adler et al. 1990; Baker et al. 1987 Baker et al. , 1990 . Further more, the defIcit in P50 gating in the manic patients is correlated with increased plasma levels of 3-methoxy4hydroxy-phenyl-glycol (MHPG), a norepinephrine metabolite. Similarly, the cold pressor test, which has been associated with increasing noradrenergic neuronal transmission, has been shown to cause a transient im pairment in P50 auditory sensory gating in normal con trol subjects (Johnson and Adler 1993) . Two drugs known to produce psychosis in humans, phencyclidine (PCP) and dextroamphetamine, which increase central catecholaminergic neuronal transmission, also impair auditory sensory gating in an animal model (Adler et al. 1986 (Adler et al. , 1988 Bickford-Wimer et al. 1990; Stevens et al. 1991; Miller et al. 1992) .
Although this converging evidence from animal and clinical studies suggests increased noradrenergic neuronal transmission as one mechanism that decreases auditory sensory gating, the data from humans is only correlational. The aim of this study was to assess whether increasing central noradrenergic neuronal transmission would transiently impair P50 auditory sen sory gating in a group of normal control subjects. One pharmacologic probe that has been used to selectively increase central noradrenergic neuronal transmission is yohimbine, a presynaptic a-2 antagonist. Yohimbine has precipitated acute manic episodes in some subjects (Price et al. 1984) and has precipitated panic attacks in patients with a history of panic disorder . It also causes an increased amplitude in the acoustic startle reflex in human subjects (Morgan et al. 1993) . The peak effects of yohimbine's action in pre cipitating panic attacks and its effects on acoustic star tle coincide with its peak effects on plasma catechol a mines, that is, less than 30 minutes after ingestion. In animal studies, yohimbine causes a transient impair ment in gating of auditory evoked potentials (Stevens et al. 1993) . In this study, we used the same dose, 0.4 mg/kg, that precipitated panic disorder in predisposed individuals. Using yohimbine as a pharmacologic probe, we were able to assess the effects of a sudden rapid increase in CN S noradrenergic neuronal trans mission on P50 auditory sensory gating.
METHODS

Subjects
Seven normal controls with no personal history of men tal illness were recruited. None had a family history of a psychotic disorder, although one had a history of an affective disorder in a fIrst-degree relative. All were be tween 21 and 35 years old. All met Research Diagnos tic Criteria for Never Mentally III (Endicott and Spitzer 1978) . Five subjects were men, two were women. All had a college degree or some graduate education. None of the subjects were being treated with medications at the time of the study, none had any illness, and none had ever abused drugs or alcohol. All subjects gave writ ten informed consent prior to their participation in the study. NEUROPSYCHOPHARMACOLOGY 1994-VOL. 10, NO.4 Experimental Protocol Subjects were admitted to the Clinical Research Cen ter of the University of Colorado Hospital between 8:00 and 9:00 A.M. on two different days, at least one week apart. Subjects had been fasting since midnight and had been asked to refrain from any alcohol or over-the counter medication use for the previous 48 hours. They were given one to two hours to acclimate to the labora tory setting, and evoked potentials were recorded to familiarize the subject with the procedure. Up to three recordings were performed until there was gating of the P50 response to the test stimulus. Each set of evoked potentials consisted of 16 trials. Two sets of baseline evoked potentials were then obtained. The subject was then given a gelatin capsule containing either 0.4 mg/kg of yohimbine or placebo; the order of administration was decided by randomization. Four subjects received yohimbine the fIrst day, and three subjects received placebo the fIrst day. Each subject completed both the placebo and drug portions of the study. Subjects were given at least one week between study days; most sub jects had two to three weeks between experimental days.
Beginning 15 minutes after drug administration, three 16-trial sets of evoked potentials were recorded. In each case, the post-drug recordings were completed by 30 to 35 minutes after drug administration. Two 16-trial sets of evoked potentials were recorded one hour after drug administration, and an additional set was recorded two hours after drug administration. Only one averaged evoked potential for one subject was dis carded due to artifact. Up to 20% of trials were rejected on line because of noise. Thus, some subjects needed 20 evoked potential trials to generate one set of 16 trials. A total of 111 evoked potential averages were used in the study.
Blood pressure and pulse were recorded after the evoked potentials were completed for each time period. In addition, subjects completed a brief self-rated test, the POMS (ProfIle of Mood States, McNair et al. 1971) examination at each time period.
Evoked Potential Recording
Evoked potential recording was performed with the subjects supine and their heads well supported on pil lows. The recordings were performed and analyzed by an investigator blind to the pharmacologic treatment condition. The subjects were instructed to keep their eyes open and fIxed on a distant target. Electroen cephalographic activity (EEG) was recorded from a gold disk electrode affIxed to the vertex, referenced to nose, with a forehead ground. Electrooculogram (EOG) was recorded from electrodes on the right superior orbit and lateral canthus. The signals were amplified 20,000 times by a 22 MQ impedance amplifier with bandpass fIlters (-SO%) between 1.0 and 300 Hz (model 7pSll, Grass Instruments, Quincy, MA). The EEG was monitored on an IBM AT compatible computer (Epson Equity III, Torrance, CA) with an analog interface (Data Transla tion DT 101, Marlboro, MA). Data was acquired at 1000 Hz digitization rate. Individual trials were rejected when there was evidence of alpha waves or slow wave activity, which causes changes in PSO gating (Griffin et al. 1993) . Individual trials were also rejected or replayed off line if the tracing contained a startle re sponse to the auditory stimulus, which is seen as EOG activity greater than SO J.1 V or as a negative-positive com plex greater than SO J.1 V in the EEG occurring 30 msec after the stimulus, which reflects activity originating in the neck muscles (Robinson and Rudge 1982) . In this study, approximately 20% of trials were dropped on line due to such artifacts. Each average evoked poten tial consisted of 16 individual trials.
Auditory stimuli were presented in trains of pairs in a conditioning-testing paradigm, with O.S s intrapair interval and a 10 s inter stimulus interval. The stimu lus was an 0.04 msec pulse, amplified with a band width between 20 and 12,000 Hz and delivered through headphones. Mean intensity was 70 dB SPL, as measured at the subject's ear by a sound meter. If the subject showed startle reactions or EOG activity to the stimulus, the intensity was reduced by S dB (Freedman 1990) . One subject required such a decrease in stimulus intensity. Changes in sound intensity were not made after the baseline period.
The averages were digitally ftltered with a recur sive high-pass double-time autoregressive fIlter and a 7 point low-pass digital smoothing routine (A = 0.9S, Coppola 1979) . Each ftlter was applied twice in both the forward and reverse direction, to increase rolloff and to preserve waveform latency. Low-pass fIltering was performed by averaging each point with the three points before and after. This technique was also per formed twice. This fIltering technique causes a de crease of 70% in frequencies below 10 Hz or above 2S0 Hz. A previously described computer algorithm (Naga moto et al. 1989 ) was used to identify and quantitate PSO. The algorithm identified the conditioning PSO waveform as the most positive peak between 40 and 80 msec after the hrst stimulus. If more than one peak was identified, the later one was selected. The test PSO was identifted as the most positive peak with a laten cy from the test response within 10 msec of the laten cy of the conditioning PSO response. This criterion was determined from the distribution of conditioning and test PSO wave latencies in a previous study (Nagamo to et al. 1991) . The test amplitude was measured rela tive to its preceding negativity. The amplitude of the test PSO wave (T) divided by the amplitude of the con-PSO Gating Impairment by Yohimbine 251 ditioning PSO wave (C), expressed as percent and termed here the TIC ratio, was used as a measure of sensory gating.
Sixteen trial averages were used because the speed of the yohimbine effect precluded the use of longer recording periods. To assess whether the condition ing and testing response could be discriminated from noise in such averages, a set of 16 single trial record ings and their average were analyzed. The time points used for measurement of the PSO and the preceding negativity were established in the average waveform for both the conditioning and testing response. An equal time period was demarcated in the pre stimulus period, ending at the delivery of the conditioning stimulus. Then, the amplitude measurements of pre stimulus activity, the conditioning PSO wave, and the test PSO wave were made in each of the 16 individual responses, using these time points. To estimate the variability of each measure, the mean value was divid ed by the standard error of the mean to determine a Student's t-score with IS degrees of freedom. Single tailed probability values were used because of the as sumption that PSO is positive. The t-score for the pre stimulus activity was 0.01 (NS), whereas the t-score for the poststimulus conditioning wave was 1.87 (p < .OS) and for the poststimulus test wave was 1.90 (p < .OS). Thus, the PSO waves measured in the 16 trial par adigm are a statistically significant characteristic of the poststimulus evoked response, distinguishable from background activity.
Statistical Analysis
Because of the small sample size and because of the different number of trials in each time period, the ex periment was initially planned and analyzed as a ran domized block design analysis of variance (ANOV A) with two treatment effects (placebo and drug) and four time effects (baseline, 30 minutes post, 1 hour post, and two hours post). Post hoc t-tests were performed for comparison of individual contrasts only if protected by a significant ANOVA (Wilkinson 1990) . A repeated measure ANOV A was then calculated using the means for each subject for each treatment at each time. Only four planned t-tests were done. Three were for pulse, systolic, and diastolic blood pressures between base line and 30 minute post-yohimbine conditions. The fourth comparison compared the PSO ratio between placebo and yohimbine at 30 minutes past drug. This comparison was planned to coincide with peak effects as assessed by previous investigators . All values are expressed as mean and standard deviation for each condition for the seven subjects. All probability values are two-tailed unless speciftcally noted. 
84.6%
34.0% Figure 1 . Two subjects at three diff erent times: baseline, 30 minutes post drug or placebo, and 1 hour post drug or placebo for both the drug and placebo days. The first waveform in each pair is the conditioning waveform; the second waveform is the test waveform. The TIC ratio as a percentage is given below each pair. Tick marks indicate the P50 waveform as mea sured by the computer algorithm. Superimposed tick marks in the test waveform or lack of a discernible waveform between the tick marks indicate the P50 waveform is absent (zero amplitude). The first subject has TIC ratios below 32% in all three placebo conditions, but has significantly impaired P50 gating (TIC ratio = 71.6%) one half hour after 0.4 mglkg of yohimbine, which returns to the normal range of 7.4% one hour after yohimbine. The second subject has TIC ratios of 0% in all three placebo times, but has an increased TIC ratio of 84.6% one half hour after drug, which returns to 34% by one hour after drug. These two subjects illustrate the rapid, but relatively brief impairment of P50 auditory gating caused by a sudden increase in noradrenergic neuronal transmission.
RESULTS
Administration of yohimbine caused a transient but pro nounced impairment in P50 auditory sensory gating. Figure 1 shows representative waveforms from two sub jects at the baseline, 30 minute, and one hour time in tervals. For each of these two subjects shown, the TIC ratio peaked within 30 minutes after yohimbine and the effect was lost by one hour. Figure 2 shows a similar effect on the mean ratios for all seven subjects. An analysis of variance pooling averages from all subjects permitted use of all ratios obtained, even if different subjects did not have equal numbers of aver aged evoked potentials at each time period. This analysis showed a signifIcant effect of treatment (F = 8.00, df = 1,103, p< .006) but not of time (F = 2. 45, df = 3,103, P < .07) or of treatment by time (F = 1.13, df = 3,103, NS). An analysis of variance was also done examining the effect of treatment, subject, and treatment by sub ject interaction on the P50 ratio. Once again, there was a signifIcant effect of treatment (F = 8.22, df = 1,97, P < .005), but not of subject (F = 0.995, df = 6,97, P < .433) or of subject by treatment (F = 0.995, df = 0.113, P < .995). The means for each subject under each treat ment condition were then used in a univariate repeated measures analysis of variance, which also showed a signifIcant effect of yohimbine treatment (F = 9.65, df = 1,12, P < .01), but no overall signifIcant effect of time ····v.
BASELINE 30 MIN 1 HR 2 HRS TIME POST DRUG Figure 2 . Maximum effect of yohimbine on each subject. P50 TIC ratio (%) on the vertical axis versus time after drug ad ministration on the horizontal axis. All values are mean ± SEM. There is a signifIcant difference between the yohimbine and placebo curves (F = 8. 00, df = 1, 103, P < .006). The planned t-test between yohimbine and placebo is signifIcant at one half hour post drug (t = 2.64, df = 40, P < .01) and is indicated by an asterisk.
(F = 1.41, df = 3,36, P < .26, NS) or of treatment by time (F = 0.88, df = 3,36, p< .46, NS). However, there was a signifIcant diff erence between TIC ratios at 30 minutes after drug versus placebo administration when the 21 placebo and 21 yohimbine evoked potential aver ages were compared. The mean TIC ratio 30 minutes post yohimbine was 85.4% ± 70.8%, versus 37.7% ± 43.2% post-placebo (t = 2.64, df = 40, P < .01). By one and two hours after the administration of yohimbine, the treatment effect had largely disappeared. Figure 3 shows the mean baseline PSO ratios and the maximal PSO ratios reached during the frrst hour after yohim bine treatment for each of the seven subjects. Two hours after the drug was administered, two of the seven sub jects still had signifIcantly elevated TIC ratios, although the remaining fIve had returned to TIC ratios below 50%. This is the explanation for the increased variance observed at the two hour mark. There was no signifIcant effect of yohimbine on ei ther PSO conditioning amplitude or on latency (Tables  1 and 2 ). However, for amplitude, both the overall ANOV A (F = 3.21, df = 3,103, P < .03) and the univari ate repeated measures ANOVA (F = 6.13, df = 3,36, P < .002) showed a signifIcant effect of treatment time within subjects, but not of treatment by time. As can be seen in Table 1 , the largest decrease in overall means Figure 3. The fIgure shows the mean baseline for each sub ject on the day the subject took yohimbine followed by the increased P50 TIC ratio for each subject after yohimbine treat ment. The vertical axis is the P50 (TIC) ratio expressed as a percentage. The mean baseline is the mean of the two base line averages for each subject. Each subject is indicated by a different symbol and different line. All but one subject had P50 ratios of less than 40%. Five of the subjects had baseline P50 ratios less than 30%. Four of the subjects clustered at ap proximately 20%, which is the reason for the overlapping sym bols in the Baseline column. The column "Maximum Ratio" shows the maximum effect of yohimbine for each subject at either 30 minutes or 1 hour after drug ingestion. Five of the seven subjects had peak P50 ratios at 30 minutes post drug, whereas two of the subjects had a delayed peak at 1 hour post drug. The lines connect the baseline value to the maximal post treatment value for each subject. The maximal P50 ratios graphed represent the means of two to three averages for each subject. All but one subject returned to P50 TIC ratios of less than 40% at two hours post drug. Four of the subjects had returned to P50 TIC ratios of less than 10% at 2 hours post drug.
occurred at the one hour time interval. Because of the signifIcant effect of time on amplitude, we also looked for an effect of amplitude on PSO ratio. There was a small but signifIcant correlation between amplitude and PSO ratio, r = -0.24, P < .01, accounting for 5.8% of the Yohimbine Placebo 4.4 ± 2.3 5.1 ± 3.4 3.1 ± 2.5 3.3 ± 2.6 3.1 ± 2.6 2.5 ± 1.8 4.4 ± 2.3 3.7 ± 1.9
All values are in J.lV, mean ± SO.
variance in the PSO ratio. An analysis of covariance on ratio could not be performed because there was a signihcant interaction between treatment and ampli tude, indicating nonparallel slopes. However, in any use of the general linear model on a ratio measure, there is the possibility that a correlation between a linear mea sure (amplitude) and a nonnormally distributed non linear measure (ratio) could be spurious. Therefore, we used the logarithmic transformation of the PSO ratio in a second ANOV A. In order to avoid dropping data points, any PSO ratio of zero was recoded as .001, since zero cannot be logarithmically transformed. Because the initial analysis of variance did not yield a signihcant treatment by amplitude interaction, an analysis of covariance was performed. Drug treatment was sig nihcant (F = S.S, df = 1,94, P < .021). In the analysis of covariance, the effect of amplitude just missed signincance (F = 3.63, df = 1,94, P < .06). In this case, the Pearson's correlation between amplitude and the log of the PSO ratio was only 0.20, p < .IS, NS. Thus, when a logarithmic transformation of the PSO ratio was used, there was no signihcant linear correlation between amplitude and sensory gating, nor was there a direct effect of amplitude on PSO ratio in the analysis of covar iance. The effect of yohimbine on pulse and blood pres sure was compared as a difference between the base line and half-hour treatment values for the placebo and drug days. There were no signihcant differences among trials for the placebo day. On the drug day, the only effect of yohimbine was on systolic blood pressure 30 minutes after drug treatment. Mean systolic blood pres sure prior to treatment was 100. 9 mm Hg and after drug was 113. 1 mm Hg (paired t-test = 2.9, df = 6, p< .028).
There were no signihcant effects on diastolic blood pres sure or pulse, nor were there any other differences at the other time intervals. Finally, none of the subscales of the POMS changed signihcantly during the experi ment, although all seven subjects felt "tired" and rest less at the end of both days. Administration of yohimbine transiently impaired PSO auditory sensory gating in this normal control popula tion. A small but signincant increase in systolic blood pressure was noted at the 30 minute post drug time point, which was consistent with previous investiga tors. Since the evoked responses were recorded prior to obtaining vital signs, the blood pressures were taken later than the usual peak 20 minute time point; thus we might have inadvertently biased the experiment against nnding an even larger difference in systolic blood pressures. We did not expect to see changes in a behavioral rating scale in young, healthy subjects. However, most reported some subjective stress by the end of the lengthy recording sessions, both in placebo and drug conditions.
Although yohimbine principally increases nor adrenergic neuronal transmission, at high dosages yo himbine may also bind dopaminergic autoreceptors, thus increasing dopaminergic neuronal transmission as well (Scatton et al. 1980 ). However, Stevens et al. (1993) , found that co administering SCH 23390, a selec tive 0 1 antagonist with yohimbine, did not block the yohimbine-induced impairment in auditory sensory gating in an animal model. Similarly, Gurgius and Uhde (1990) found that 20 mg of yohimbine did not sig nihcantly increase plasma HV A levels, even in patients prone to panic disorder. Thus, the action of yohimbine on auditory gating would appear to be mediated by nor epinephrine.
Evidence from animal studies suggests that gating of the N40 waveform in the rat, which behaves homolo gously to the PSO waveform in human subjects, has its origins in CA3 of the hippocampus (Bickford-Wimer et al. 1990; Miller et al. 1992) . Depth probe studies in human subjects suggest that the PSO waveform also may have its origins either in the superior temporal lobe or in hippocampus . In ani mals, nor epinephrine decreases synaptic inhibition in rat hip- pocampus, through both presynaptic and postsynap tic mechanisms (Madison and Nicoll 1988; Newberry and Nicoll 1984; Dutar and Nicoll 1988) . The impairment of auditory sensory gating by nor epinephrine may be relevant to disorders in which au ditory sensory gating is impaired when patients are acutely ill, such as mania and other illnesses in which there is increased noradrenergic neuronal transmission Adler et al. 1990; Baker et al. 1987 ). In contrast, schizophrenic patients and half of their fust degree relatives appear to have impaired P50 auditory gating as a trait rather than as a state defIcit (Siegel et al. 1984; Freedman et al. 1991) . In schizophrenic patients, this impairment of P50 audi tory gating persists even when they are treated with enough neuroleptic to cause mild extrapyramidal symp toms Adler et al. 1990 ). Such dosages probably block both dopamine and norepi nephrine at the postsynaptic receptor (Freedman 1977) . These fIndings suggest that state-dependent, revers ible defIcits in P50 gating may be due to increased nor adrenergic neuronal transmission (Waldo et al. 1992) , but that in schizophrenia, in which the P50 gat ing defIcit appears to be an inherited triat Siegel et al. 1984) , the defIcit may be more related to defIcits in other neurotransmitter systems. For ex ample, impairment of nicotinic transmission to area CA3 of the hippocampus results in direct impairment of auditory gating (Luntz-Leybman and Freedman 1992) , and nicotine normalizes P50 gating in schizo phrenics and their relatives .
